Prostate Cancer
Conditions
Keywords
Intermediate Risk Prostate Cancer, Low Risk Prostate Cancer, Active Surveillance
Brief summary
Description: Multicentre observational study, not randomized. Ambispective character (retro and prospective). Opened to any member of the Asociación Española de Urología (AEU), public and private medicine. Justification: Active surveillance is a strategy proposed to control the overtreatment derived from the opportunist screening in prostate cancer (PCa). Its development in our country is erratic and different in every Center. This database tries to include most of patients included in active surveillance in Spain with a few minimal inclusion criteria. Multicentre registry and follow up of the active surveillance in Spain. Hypothesis: Mortality cancer specific for PCa includible in active surveillance to 15 years is lower than 5 %.
Interventions
OTHERRegistry
National Registry of patients with prostate cancer as monitored through active surveillance, with the intention of testing the hypothesis that cancer-specific mortality in very low-risk and low-risk patients is less than 5% at 15 years.
Sponsors
Fundación Instituto Valenciano de Oncología
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
MALE
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. PSA ≤ 10 ng / mL; if prostate volume\> 60 cc in transrectal, ultrasound includable with PSA\>10 ng / ml if PSAD \<0.20 2. Local Stadium DRE; cT1c -cT2a 3. Diagnosis of transrectal ultrasound guided biopsy minimum 10 cylinders 4. Adenocarcinoma Prostate Gleason ≤ 6 (3 + 3) with local and central pathology review 5. Maximum number of cylinders = 2 and none of them more than 5mm tumor or more than 50% of assignment 6. \<80 years and greater expectancy to 10 years life (Charlson score) 7. Patients able to understand active surveillance and sign the Informed Consent
Exclusion criteria
1. Patient not be able to accept up with repeat biopsies 2. Patient who does not want to sign the Informed Consent 3. Hospital where the possibility of a biopsy confirmation at 6 months is not guaranteed under the terms of the inclusion criteria 4. Patients with a history of ASAP (atypical small acinar proliferation or atypical microglands) 5. Patients with treatment with inhibitors of 5-alpha-reductase as dutasteride (Avidart®) and finasteride (Proscar®) during the previous six months 6. Patients who have undergone during the 6 months prior to any treatment symptomatic benign prostate hyperplasia, or any invasive urological procedure. It can be associated with an increase of PSA prior to phlebotomy. These therapies include, but they are not limited to, prostate biopsy, thermotherapy, microwave therapy, laser, urethral resection of the prostate, urethral catheterization and the lower genitourinary tract endoscopy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Active treatment-free interval | Date start active surveillance-stop active surveillance due to active treatment, or up to 15 years, whichever came first | Time to active treatment will be recorded, independently of each Center protocol, from enrollment to any other active due to prostate cancer progression or patient desire to receive any active treatment Estimated active treatment free survival will be analyzed at 2, 5 and 10 years from initiation of the protocol. |
| Cancer specific survival in patients in active surveillance | up to 15 years | Global CSS will be recorded, independently of each Center protocol, from enrollment to death due to PRostate Cancer Estimated CSS will be analyzed at 5, 10 and 15 years from initiation of the protocol. To this purpose, patients will be followed although they progressed and went into active treatment. |
| Overall survival | Date randomization-date death, or up to 15 years, whichever came first | Global OS will be recorded, independently of each Center protocol, from enrollment to death of any cause Estimated OS will be analyzed at 5, 10 and 15 years from initiation of the protocol To this purpose, patients will be followed although they progressed and went into active treatment or if the kept in active surveillance till their death due to any cause. |
| Characterization of pathologically agressive tumors by Gleason score | From the study start and stop until 15 years | Characterization of pathologically agressive tumours will be done by analyzing the pathological reports of radical prostatectomy specimens derived from patients included in the protocol that went on to radical prostatectomy. This has no time frame, although time of radical prostatectomy will be a variable to take in account for comparisions among different timings of performace of radical prostatectomies. |
| Characterization of pathologically agressive tumors by TNM | From the study start and stop until 15 years | Characterization of pathologically agressive tumours will be done by analyzing the pathological reports of radical prostatectomy specimens derived from patients included in the protocol that went on to radical prostatectomy. This has no time frame, although time of radical prostatectomy will be a variable to take in account for comparisions among different timings of performace of radical prostatectomies. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Quality of Life in patients with active surveillance | up to 5 years | Assessed with CAVIPRESS-30 questionaires |
Countries
Spain
Contacts
Primary ContactJose Rubio Briones, MD, PhD
Backup ContactÁngel Borque Fernando, MD, PhD
Outcome results
None listed